You may have heard of the Chinese business concept of guanxi, but do you really understand it? The term, loosely defined as "relationship," can be maligned in the West, but there's more to it than cronyism.
Continue reading "How's Your Guanxi?" »
Check out these headlines covering the Middle East and North Africa (MENA) in "PharmAsia News".
Continue reading "Have you seen our M.E.N.A Coverage? " »
Full article preview from The RPM Report January 27, 2009
The Obama Administration is understood to have made its choice for the next head of the Medicare agency. Will it be an MD? Find out now...
Continue reading "CMS Administrator: The Pick Has Been Made, But Who Is It? " »
Article preview from "The Pink Sheet" January 20, 2009
Find out why The Senate confirmation of a permanent FDA commissioner could come as early as March now that the Obama transition team has apparently concluded its search for Andrew von Eschenbach's successor...
Continue reading "Race For White Oak Almost Over: Will It End With Sharfstein Or Califf At FDA? " »
Full article reprinted from The RPM Report January 20, 2009
We know you've been waiting on the edge of your seat so we thought we'd send you an update. We've heard that Duke researcher Robert Califf and Baltimore Commissioner of Health Joshua Sharfstein have been tapped, at the very least, for interviews. Read more now...
Continue reading "FDA Commissioner Update: Califf's Name Emerges But Is Sharfstein the Pick?" »
Full article reprinted from The RPM Report January 13, 2009
Former FDA Commissioner Jane Henney’s name has surfaced for a possible return to FDA. Whether she’s in the running for the job, or it’s just the Washington rumor mill in action, she would be a safe pick for the incoming administration. Read more about it here...
Continue reading "The Return of Henney? " »
Article preview from "IN VIVO" December 23, 2008
Pharma has weathered its share of economic downturns, but the data shows that the industry could be in for a tough winter. Prolonged cutbacks by consumers failing to refill prescriptions in tough economic times could become yet another obstacle for drug manufacturers already facing plenty of challenges in the coming year in the form of patent expirations, lackluster pipelines and stricter regulatory oversight. Find out more...
Continue reading "Economic Forecast for Pharma: Winter Weather Advisory Ahead" »